Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Fig. FACS analysis of Transferrin R on HEK293/Human Transferrin R Stable Cell Line.
FACS assay shows that Anti-Transferrin Receptor antibody can bind to HEK293/Human Transferrin R Stable Cell Line. HEK293/Human Transferrin R Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Human Transferrin R Protein, Fc Tag (Cat. No. TFR-H5264) captured on Protein A Chip can bind Human Transferrin, His Tag with an affinity constant of 0.491 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Immobilized Biotinylated Mouse Transferrin R Protein, His,Avitag (Cat. No. TFR-M82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Mouse Transferrin Protein, Mouse IgG2a Fc Tag (Cat. No. TRN-M525b) with a linear range of 0.2-6 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | Iron Metabolism Disorders; beta-Thalassemia | Details | |
CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
DYNE-251 | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
Delpacibart eteddesiran | AOC-1001 | Phase 2 Clinical | Avidity Biosciences Inc | Myotonic Disorders; Genetic Diseases, Inborn; Musculoskeletal Diseases; Muscular Disorders, Atrophic; Myotonic Dystrophy; Muscular Atrophy; Muscular Diseases; Heredodegenerative Disorders, Nervous System; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Neurodegenerative Diseases | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
This web search service is supported by Google Inc.